Education
About Us
Working with TipRanks
Follow Us
Scinai Immunotherapeutics (SCNI)
NASDAQ:SCNI
SCNI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.40 - $6.18
Previous CloseN/A
Volume8.73K
Average Volume (3M)2.19M
Market Cap
$1.31M
Enterprise Value$8.60M
Total Cash (Recent Filing)$1.03M
Total Debt (Recent Filing)$1.23M
Price to Earnings (P/E)0.3
Beta1.23
Next Earnings
Nov 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.72
Shares Outstanding933,679
10 Day Avg. Volume237,632
30 Day Avg. Volume2,193,871
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap6.59
Enterprise Value/Revenue19.02
Enterprise Value/Gross Profit-20.81
Enterprise Value/Ebitda1.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Scinai Immunotherapeutics News
SCNI FAQ
What was Scinai Immunotherapeutics’s price range in the past 12 months?
Scinai Immunotherapeutics lowest stock price was $1.40 and its highest was $6.18 in the past 12 months.
What is Scinai Immunotherapeutics’s market cap?
Scinai Immunotherapeutics’s market cap is $1.31M.
When is Scinai Immunotherapeutics’s upcoming earnings report date?
Scinai Immunotherapeutics’s upcoming earnings report date is Nov 26, 2025 which is in 83 days.
How were Scinai Immunotherapeutics’s earnings last quarter?
Scinai Immunotherapeutics released its earnings results on Aug 21, 2025. The company reported -$3.716 earnings per share for the quarter, missing the consensus estimate of N/A by -$3.716.
Is Scinai Immunotherapeutics overvalued?
According to Wall Street analysts Scinai Immunotherapeutics’s price is currently Overvalued.
Does Scinai Immunotherapeutics pay dividends?
Scinai Immunotherapeutics does not currently pay dividends.
What is Scinai Immunotherapeutics’s EPS estimate?
Scinai Immunotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 933,679 shares outstanding.
What happened to Scinai Immunotherapeutics’s price movement after its last earnings report?
Scinai Immunotherapeutics reported an EPS of -$3.716 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.338%.
Which hedge fund is a major shareholder of Scinai Immunotherapeutics?
Currently, no hedge funds are holding shares in SCNI
Company Description
Scinai Immunotherapeutics
Scinai Immunotherapeutics (SCNI) is a biopharmaceutical company focused on the development and commercialization of novel immunotherapeutic products. Operating within the biotechnology and healthcare sectors, SCNI specializes in creating innovative treatments aimed at harnessing the body's immune system to combat various diseases. The company is dedicated to advancing its pipeline of proprietary immunotherapy candidates, addressing critical unmet medical needs across a range of indications.
Technical Analysis
TNF Pharmaceuticals
―
Entero Therapeutics
―
Protagenic Therapeutics
―
ZyVersa Therapeutics
―
PMGC Holdings
―
Ownership Overview
7.40%
Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
92.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---